Mediclinic, a leading diversified international private healthcare services group, announces the appointment of two new independent non-executive directors: Natalia Barsegiyan and Zarina Bassa.
Dame Inga Beale, Chair of Mediclinic, commented: “The Board is delighted to welcome Natalia and Zarina as independent non-executive directors of the Company. Each will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”
Natalia Barsegiyan is currently a non-executive director of Domino’s Pizza Group plc, the FTSE 250 digitally-enabled, quick service international restaurant group and is a member of their Audit Committee. She also acts as an adviser to Kharis Capital, a private equity firm based in Belgium. Prior to this, the majority of Natalia’s career was with the US group Yum! Brands, Inc., owner of a portfolio of many well-known brands such as KFC, Pizza Hut and Taco Bell, where she served as Chief Commercial Officer of the Group and then Chief Financial Officer of Taco Bell. Her appointment as a director of Mediclinic will become effective on 1 August 2021. Natalia will bring a strong finance background with a commercial and strategic focus, an in-depth understanding of the use of data analytics to support transformation and broad international experience, having lived and worked across the US, Europe, Russia and the UK.
Zarina Bassa is currently the senior independent director of Investec plc and Investec Ltd, the specialist banking and wealth management group with a dual listed company structure and listings on the London and Johannesburg Stock Exchanges; lead independent director of Woolworths Holdings Ltd; and non-executive director of JSE Ltd and Oceana Group Ltd (the last three all being South African companies with a listing on the Johannesburg Stock Exchange). Zarina has stepped down today as Chair of Yebo Yethu Ltd and previously served as a non-executive director at several other companies including Kumba Iron Ore Ltd; Mercedes Benz SA Ltd; Sun International Ltd; Vodacom South Africa Proprietary Limited; the South African Institute of Chartered Accountants; and the Financial Services Board. Prior to that, she was a partner of Ernst & Young Inc. and then joined the Absa Group in 2002, where she served as an executive director of Absa Bank, a member of the group’s executive committee, and Head of the Private Bank. Zarina’s appointment as a director of Mediclinic will become effective on 1 February 2022. The Board of Mediclinic has carefully considered Zarina’s existing time commitments and is satisfied that she will have sufficient time to dedicate to fulfil her responsibilities to the Group. She will contribute strategic and operational experience in complex, regulated environments, a strong financial and accounting background, and diverse experience in listed companies across a breadth of sectors and jurisdictions.
CHANGES TO BOARD COMMITTEES
Following a review of the Board Committee structure and responsibilities, the Board has decided to separate the responsibilities of the Clinical Performance and Sustainability Committee, to allow for more time to dedicate to the oversight of these key aspects of the Group’s strategy and operations. Accordingly, with effect from 1 September 2021:
- the Clinical Performance and Sustainability Committee will become a focused Clinical Performance Committee. There will be no change in its composition; and
- a new Environmental, Social and Governance Committee will be established, chaired by Dame Inga, with other members comprising: Dr Ronnie van der Merwe, Natalia Barsegiyan, Dr Felicity Harvey and Danie Meintjes.
- Natalia Barsegiyan will also join the Audit and Risk Committee upon her appointment as a non-executive director;
- Zarina Bassa will join the Audit and Risk and Remuneration Committees when her appointment as non-executive director becomes effective;
- Dr Muhadditha Al Hashimi will join the Remuneration Committee on 13 September 2021; and
- Tom Singer will join the Investment Committee on 13 September 2021.
Other changes to roles and responsibilities of other directors will also proceed as announced by the Company on 26 May 2021.
This announcement is made in accordance with the requirement of LR 9.6.11. There are no disclosures required pursuant to paragraphs (1) to (6) of LR 9.6.13 R of the United Kingdom Listing Authority’s Listing Rules in respect of these appointments.